Veraxa Biotech AG VRXA
- Market cap
- $217.0M
- P/E
- —
Follow VRXA
Target Price Range
Analyst price targets
Free account| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | 9.95 | 10.03 | 1.27 |
Analyst estimates 2027–2029 Powerpack |
Low Price
|
||
| — | — | — | — | — | — | — | 11.20 | 10.99 | 27.36 |
High Price
|
|||
| — | — | — | — | — | — | — | — | — | — | Employees | |||
| — | — | — | — | — | — | — | — | — | — | Revenue/Emp | |||
| — | — | — | — | — | — | — | — | — | — | Revenue | |||
| — | — | — | — | — | — | — | — | — | — | Gross Margin | |||
| — | — | — | — | — | — | — | — | — | — | EBT | |||
| — | — | — | — | — | — | — | — | — | — | EBT Margin | |||
| — | — | — | — | — | — | — | — | — | — | Net Income | |||
| — | — | — | — | — | — | — | — | — | — | Depreciation | |||
| — | — | — | — | — | — | — | — | — | — | Revenue/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Earnings/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Cash Flow/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Capex/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Free CF/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Book Value/Sh | |||
| — | — | — | — | — | — | — | — | — | — | Shares | |||
| — | — | — | — | — | — | — | — | — | — | PE Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PS Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PB Ratio | |||
| — | — | — | — | — | — | — | — | — | — | EV/Sales | |||
| — | — | — | — | — | — | — | — | — | — | EV/FCF | |||
| — | — | — | — | — | — | — | — | — | — | Op' Cash Flow | |||
| — | — | — | — | — | — | — | — | — | — | Capex | |||
| — | — | — | — | — | — | — | — | — | — | FCF | |||
| — | — | — | — | — | — | — | — | — | — | Working Cap' | |||
| — | — | — | — | — | — | — | — | — | — | Total Debt | |||
| — | — | — | — | — | — | — | — | — | — | Net Debt | |||
| — | — | — | — | — | — | — | — | — | — | Sh' Equity | |||
| — | — | — | — | — | — | — | — | — | — | ROA | |||
| — | — | — | — | — | — | — | — | — | — | ROIC | |||
| — | — | — | — | — | — | — | — | — | — | ROE | |||
Veraxa Biotech AG peers in Biotechnology
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| AVXL Anavex Life Sciences Corp. | $216.9M | 0.0× | Compare |
| ALEC Alector, Inc. | $214.4M | 0.0× | Compare |
| WHWK Whitehawk Therapeutics, Inc. | $220.1M | 0.0× | Compare |
| FHTX Foghorn Therapeutics Inc. | $213.8M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| PLX Protalix BioTherapeutics, Inc. | $221.6M | 11.3× | Compare |
| CGEN Compugen Ltd. | $224.5M | 6.3× | Compare |
| ELDN Eledon Pharmaceuticals, Inc. | $228.3M | 0.0× | Compare |
| KROS Keros Therapeutics, Inc. | $229.0M | 0.0× | Compare |
Veraxa Biotech AG (VRXA) Latest News
24 Sep
VERAXA Biotech (VRXA) is shifting its focus to advancing its oncology pipeline and forging industry partnerships after completing its business combination and Nasdaq listing in June 2026. Xlife Sciences reports a financing base to support upcoming development and retains VERAXA as a key portfolio component. The broader Xlife Sciences portfolio reported progress across x-kidney diagnostics, saniva diagnostics, Axenoll, FUSE-AI and inflamed pharma, with 416 patents and 216 granted IP rights. In H2 2026, Xlife plans to continue backing VERAXA in establishing partnerships while pursuing commercialization and further development of its programs. VERAXA emphasizes its BiTAC antibody formats and ADC platforms as it advances toward clinical development and beyond. Financing support, Nasdaq-listed status, and focus on oncology partnerships position VRXA for a meaningful shift in development and investor sentiment.
22 Sep
VERAXA Biotech AG is building an oncology pipeline around its BiTAC platform, plus antibody-drug conjugates and engineered antibodies. The company entered the NASDAQ in June 2026 after completing a business combination with Voyager Acquisition Corp, granting access to U.S. public markets as programs advance. BiTAC is an AND-gated approach: two components must engage the same cancer cell before the cytotoxic mechanism activates. VERAXA has reported early preclinical results for BiTAC-TCE (T-cell engager) and BiTAC-ADC, including an in vitro proof of concept for BiTAC-ADC announced in June. Recent corporate moves include appointing Raju Willener as chief financial officer and Christoph Erkel, Ph.D., as chief scientific officer, adding financial and antibody-development expertise. The company also disclosed financing arrangements tied to the NASDAQ listing, including a $27.5 million senior secured note. Nasdaq listing, new senior leadership appointments, and the $27.5 million financing materially bolster VERAXA's ability to advance its BiTAC pipeline.
18 Sep
Veraxa Biotech (VRXA) appoints capital markets veteran as CFO while advancing BiTAC oncology pipeline. CFO hire supports funding and pipeline progress indicates steady oncology development without major trajectory shifts.
16 Sep
VERAXA Biotech (VRXA) is building a new approach to precision cancer therapy. New precision cancer therapy approach represents major product innovation with strong potential to shift company trajectory.
28 Aug
Veraxa Biotech (VRXA) reaches milestone in Secarna partnership, opening new potential market for conjugation technology. Secarna partnership milestone creates expanded market opportunities for Veraxa Biotech's conjugation technology.
24 Aug
Veraxa Biotech AG builds an antibody-based cancer pipeline centered on dual-targeting precision. Dual-targeting antibody pipeline development represents major strategic progress that can significantly alter company trajectory.
VERAXA Biotech and Secarna Pharmaceuticals reached a research milestone in their Antibody Oligonucleotide Conjugate alliance. Research milestone advances Veraxa Biotech AOC development efforts.
6 Aug
Veraxa Biotech advances VXA-222 cancer program while expanding patent portfolio for next-generation antibody technologies. Cancer program advancement plus patent expansion signals major strategic moves likely to alter company trajectory.
30 Jul
Veraxa Biotech (VRXA) appoints new CSO to strengthen scientific leadership and advance BiTAC cancer therapy platform. New CSO appointment aids platform development with moderate effects on operations and positioning.
29 Jul
VERAXA Biotech (VRXA) expands its patent portfolio to support next-generation cancer therapy platforms. Patent expansion directly bolsters Veraxa Biotech AG's intellectual property foundation for core cancer therapy innovation and market positioning.
Veraxa Biotech AG strengthens its patent portfolio to protect core technology platforms and product candidates. Patent strengthening secures legal protection for core biotech technologies and candidates, supporting sustained competitive positioning.
28 Jul
VERAXA Biotech shareholders approved corporate governance and financing measures. Shareholder approvals enable potential financing and governance changes that can affect company operations.
27 Jul
VERAXA Biotech (VRXA) advances its bispecific ADC program under OmniAb collaboration. Bispecific ADC program advancement under collaboration marks major pipeline progress likely to shift VRXA trajectory.
Veraxa Biotech advances VXA-222 bispecific antibody drug conjugate program from joint discovery collaboration with OmniAb. VXA-222 advancement strengthens Veraxa's bispecific ADC pipeline through OmniAb partnership.
24 Jul
Veraxa Biotech AG appoints Christoph Erkel as Chief Scientific Officer. New chief scientific officer may steer research direction and innovation efforts.
23 Jul
VERAXA Biotech (VRXA) received positive regulatory feedback from Germany on its BiTAC(R)-TCE development program. Positive German regulatory feedback advances VERAXA Biotech's BiTAC(R)-TCE program and is likely to improve future prospects and market performance.
Veraxa Biotech appoints Christoph Erkel as Chief Scientific Officer to advance BiTAC technology platforms and portfolio. CSO hire targets core BiTAC platform advancement and may influence innovation and positioning.
20 Jul
VERAXA Biotech (VRXA) receives regulatory feedback for BiTAC-TCE cancer therapy platform. Regulatory feedback advances BiTAC-TCE cancer therapy platform development.
Veraxa Biotech AG reports regulatory progress in its BiTAC®-TCE development plan. Regulatory progress on BiTAC®-TCE development advances Veraxa Biotech AG toward potential product approvals and market entry.
15 Jul
Veraxa Biotech (VRXA) is positioned to gain more than peers from AI applications accelerating drug R&D efficiency, innovation speed, and competitive positioning. AI-driven R&D improvements can materially accelerate Veraxa product pipelines and strengthen its market trajectory versus competitors.
13 Jul
VERAXA Biotech (VRXA) partners with Ardigen to advance AI-driven cancer drug development. AI partnership drives strategic pipeline acceleration and competitive gains for VRXA.
VERAXA Biotech launches AI-enabled drug discovery collaboration with Ardigen to support its growing BiTAC® pipeline. Partnership advances AI integration in drug discovery strengthening pipeline and competitive positioning.
9 Jul
VERAXA Biotech (VRXA) partners for cell line development to advance its lead BiTAC(R) T-Cell Engager Program. Cell line development partnership supports advancement of lead BiTAC T-Cell Engager program.
6 Jul
VERAXA Biotech advances BiTAC pipeline progress and partnering strategy. Pipeline progress and partnering advances signal major trajectory shifts for the biotech firm.
Veraxa Biotech AG is centering its strategy on a cancer therapy approach that the company is betting its future on. Betting the entire company on one cancer therapy strategy creates major shifts in trajectory and investor sentiment.
VERAXA Biotech issues business update with added details on partnering strategy and development timelines. Partnering strategy updates and timeline disclosures can significantly shift biotech trajectory and investor sentiment.
2 Jul
VERAXA Biotech lead cancer program reaches development milestone, placing company stock in focus. Lead cancer program milestone marks major R&D progress with potential to shift company trajectory and investor sentiment.
VERAXA Biotech (VRXA) initiates cell line development for its lead BiTAC cancer therapy program. Cell line development start advances the lead oncology program but remains an early preclinical step with limited immediate financial or market effects.
VERAXA Biotech starts cell line development with ATUM to advance its lead BiTAC®-TCE program. Collaboration to develop cell lines advances lead program and may support future pipeline progress.
1 Jul
VERAXA Biotech (VRXA) shareholders urged to monitor antibody therapeutics sector deals for effects on company value and trajectory. Sector deals may moderately shift VRXA competitive positioning without guaranteed direct company involvement.